



MOREPEN

Date: 22/01/2018

To,

National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Tel No: (022) 26598100 - 8114
Fax No: (022) 26598120
Symbol: MOREPENLAB

BSE Limited
Floor 25, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001
Phones: 91-22-22721233/4
Fax: 91-22-2272 3121
Scrip Code: 500288

Subject: Intimation of Post Results (Q3 of FY 2017-18) Conference Call of Morepen Laboratories Limited

Dear Sir,


Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that subsequent to the declaration of Financial Results for the quarter and nine-months ended 31st December 2017, the Company is organizing an 'Investor and Analyst Conference Call' on **Tuesday, 23rd January, 2018 at 2.30 p.m. (IST).**

The details of the conference call are attached herewith.

This is for your information and records.

Thanking you.

Yours faithfully,
For **Morepen Laboratories Limited**


(Thomas P. Joshua)
Company Secretary



Encl.: As Above

Morepen Laboratories Limited

Corp. Off.: 4th Floor, Antriksh Bhawan, 22 K.G.Marg, New Delhi- 110 001, INDIA
Tel.: +91-11-23324443, 23712025, E-mail: corporate@morepen.com, Website: www.morepen.com
CIN NO. L24231 HP1984PLC006028

Plant & Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205
Tel.: +91-1795-266401-03, 244590, Fax: +91-1795-244591, E-mail: plants@morepen.com



**Invite for Morepen Laboratories Ltd's Q3FY18 Post Results Conference Call on
Tuesday, 23rd January 2018 at 2.30pm**

Morepen Laboratories Ltd is one of India's leading API & Health Care diagnostics manufacturer. The company will be hosting a conference call for investor and analyst community on **Tuesday, January 23rd, 2018 at 2.30pm IST**

The call will be initiated with a brief management discussion on the company, business segments and earnings performance followed by an interactive question and answer session.

On behalf of the company the call will addressed by:

- **Mr Sushil Suri : Chairman and Managing Director**
- **Mr Ajay Sharma : Chief Financial Officer**

Details of the conference call are as follows:

Tuesday, 23rd January 2018 - 2.30 pm IST

Conference Dial-In Numbers	
Mumbai (Primary No.)	+91 22- 3960 0639
Delhi, Gurgaon (NCR), Bangalore, Kolkata, Cochin, Chennai, Pune, Lucknow, Ahmedabad, Chandigarh, Hyderabad*	+91-70456 71221
USA	18667462133
UK	08081011573
Singapore	8001012045
Hong Kong	800964448

Note: When using dial-in numbers mentioned below please do so 10 minutes prior to the conference schedule to ensure that you are connected to your call-in time.

Connect to your call without having to wait for an operator

Click on this URL or Copy this URL in your browser:

<http://services.choruscall.in/diamondpass/registration?confirmationNumber=5118872>

About Morepen Laboratories Ltd

Morepen Laboratories Limited is a 33old Rs600cr pharmaceutical and healthcare products company. The company went public in 1993 and is currently listed on both National Stock exchange and Bombay Stock Exchange.

Morepen is engaged in the manufacturing and sale of API/Bulk Drugs, Home Diagnostics, formulations, and OTC products. The company's state of the art manufacturing facility at Baddi (Himachal Pradesh) comprises a scientifically integrated complex of 10palnts, each with a specific product profile. The USFDA plant at Masulkhana is for the manufacture of Loratadine, an anti – allergy drug – internationally known as Claritin. The new blockbuster drug Montelukast is also manufactured at this FDA approved site.

The large and spread out manufacturing facility at Baddi manufactures latest and much in demand products like Atorvastatin, Rosuvastatin, sitagliptin and others for regulated markets of USA and also for non-regulated markets across the globe.

Morepen markets over 100branded formulations under six major therapeutic segments in the domestic markets. It has WHOGMP facilities for manufacturing of formulations. The company's manufacturing facilities are backed by a strong and dedicated team of research and development (R&D) professionals who ensure stringent quality standards. In home Diagnostics business, Morepen has a formidable presence in blood Glucose monitors and Blood pressure monitors in the domestic market. The company's OTC brands are being promoted under its wholly owned subsidiary Dr Morepen limited. Dr Morepen's famous OTC product line including Burnol, Lemolate, Sat-Isabgol, pain-X and others has a significant presence in domestic market.

The company's wholly owned subsidiary Dr Morepen Ltd is setting up a first of its kind chain of health care centres in India by the name of Dr Morepen Now to offer ECP Therapy to target consumers in India. The move is part of Company's "Nation on wellness (Now)" drive, which envisions providing non-invasive means to treat cardiovascular diseases and diseases associated with Cardio-metabolic issues gripping the country today. The first of its kind Dr Morepen Now clinic has been set up in Hauz Khaus, New Delhi.

For any further information please contact

Sonal Kumar Shrivastava

Kirin Advisors Pvt Ltd

Ph -9324748334

Email: Sonalkumar@kirinadvisors.com

DISCLAIMER:

Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and abroad. Actual results might differ substantially from those expressed or implied. Morepen Laboratories Ltd and its Management will not be in any way responsible for any action taken based on such statements and discussions. Morepen also undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.